Abstract Biased agonism describes a multistate model of G protein-coupled receptor activation in which each ligand induces a unique structural conformation of the receptor, such that the receptor couples differentially to G proteins and other intracellular proteins. P2Y receptors are G protein-coupled receptors that are activated by endogenous nucleotides, such as adenosine 5′-triphosphate (ATP) and uridine 5′-triphosphate (UTP). A previous report suggested that UTP may be a biased agonist at the human P2Y 11 receptor, as it increased cytosolic [Ca 2+ ], but did not induce accumulation of inositol phosphates, whereas ATP did both. The mechanism of action of UTP was unclear, so the aim of this study was to characterise the interaction of UTP with the P2Y 11 receptor in greater detail. Intracellular Ca 2+ was monitored in 1321N1 cells stably expressing human P2Y 11 receptors using the Ca 2+ -sensitive fluorescent indicator, fluo-4. ATP evoked a rapid, concentration-dependent rise in intracellular Ca 2+ , but surprisingly, even high concentrations of UTP were ineffective. In contrast, UTP was slightly, but significantly more potent than ATP in evoking a rise in intracellular Ca 2+ in 1321N1 cells stably expressing the human P2Y 2 receptor, with no difference in the maximum response. Thus, the lack of response to UTP at hP2Y 11 receptors was not due to a problem with the UTP solution. Furthermore, coapplying a high concentration of UTP with ATP did not inhibit the response to ATP. Thus, contrary to a previous report, we find no evidence for an agonist action of UTP at the human P2Y 11 receptor, nor does UTP act as an antagonist.
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Introduction
In the classical pharmacological model of drug-receptor interaction, all agonists at a G protein-coupled receptor (GPCR) activate the same G protein(s) and signalling pathways, and agonists differ only in their affinity for the receptor and efficacy in stimulating the second messenger(s). It is now clear, however, that receptors can in fact couple to different G proteins and signalling pathways in an agonist-dependent manner, a process termed biased agonism or functional selectivity [1] . For example, coupling of the D 2 -dopamine receptor to Gα i1 , Gα i2 , Gα i3 and Gα o1 varies with the agonist used [2] and the relative efficacy of 5-HT 2C agonists depends on whether phospholipase C or A 2 activity is measured [3] . Similar results have been reported for a variety of other GPCR, including μ-opioid, adrenoceptors and vasopressin receptors.
These data suggest a multistate model of GPCR activation in which each ligand induces a unique structural conformation of the receptor that couples differentially to G proteins and other proteins, such as arrestins, that interact with GPCR. Direct evidence for this model was obtained recently by imaging agonist-induced changes in the conformational structure of the β 2 -adrenoceptor [4] and arginine-vasopressin type 2 receptor [5] . In both studies, one group of agonists caused the cytoplasmic end of helix VI of the receptor to move, shifting the equilibrium towards G protein coupling, whilst another group moved the cytoplasmic end of helix VII, leading to binding of β-arrestin to the receptor. P2Y receptors are activated by endogenous nucleotides, such as adenosine 5′-triphosphate (ATP) and uridine 5′-triphosphate (UTP) [6] [7] [8] , but there are few reports of biased agonism. ATP and UTP induce differential interaction of the human P2Y 2 receptor with β-arrestins and the downstream increase in phosphorylation of ERK elicited by UTP was transient, whereas the response to ATP was prolonged [9] . Intriguingly, it has been reported that whilst ATP stimulation of the human P2Y 11 receptor caused accumulation of inositol phosphates (IPs) and a rise in cytosolic [Ca 2+ ], UTP had only the latter effect [10] . Thus, ATP and UTP appear to interact with the P2Y 11 receptor to recruit distinct signalling pathways, but how UTP produced its effects is unclear. Biased agonism has important implications for rational drug design as it raises the possibility of developing new drugs that only activate a desired, beneficial function of a GPCR, thus optimising their therapeutic effect. The aim of this study was, therefore, to investigate the mechanisms by which UTP increases cytosolic [Ca 2+ ] and so characterise biased agonism at P2Y 11 receptors in greater detail.
Methods and materials
Culture of 1321N1 cells 1321N1 cells, a human astrocytoma cell line, stably expressing the human P2Y 11 (1321N1-hP2Y 11 ) [11] or P2Y 2 (1321N1-hP2Y 2 ) [12] receptors were maintained in 5 % CO 2 , 95 % O 2 in a humidified incubator at 37°C, in Dulbecco's Modified Eagles Media (DMEM) supplemented with 10 % foetal calf serum, 1 % nonessential amino acids, 1 % penicillin (10,000 units/ml) and streptomycin (10 mg/ml). For recording intracellular Ca 2+ , the cells were plated onto 13-mm glass coverslips coated with poly-L-lysine (0.1 mg/ml). Experiments were performed once a confluent monolayer of cells had developed.
Ca
2+ imaging Intracellular Ca 2+ was monitored using the Ca 2+ -sensitive fluorescent indicator, fluo-4. Cells on a coverslip were incubated with fluo-4 AM ester (5 μM) at room temperature in the dark for at least 1 h. The coverslip was then placed in the recording chamber of a Perkin Elmer LS50B luminescence spectrophotometer and the cells superfused continuously at 4 ml/min and room temperature with buffer composed of (mM): NaCl 122; KCl 5; HEPES 10; KH 2 PO 4 0.5; NaH 2 PO 4 0.5; MgCl 2 1; glucose 11; CaCl 2 1.8, titrated to pH 7.3 with NaOH. Fluo-4 fluorescence, measured as arbitrary units (AU), in a population of cells was sampled at 10 Hz following stimulation at 494±10 nm and the emission recorded at 516 ±10 nm using FL Winlab software (V4.00.02). ATP and UTP were added in the superfusate for 90-120 s at 10-min intervals. Preliminary experiments showed that reproducible responses were evoked under these conditions. Unless indicated otherwise, data were normalised by calculating the response in AU as a percentage of the response to ATP (10 μM) (1321N1-hP2Y 11 cells) or ATP (1 μM) (1321N1-hP2Y 2 cells).
IP formation
Generation of inositol phosphates (IPs) was measured as described previously [11] . Briefly, 1321N1-hP2Y 11 
Drugs, solutions
ATP (disodium salt) and UTP (sodium salt) (Sigma/RBI, UK) were dissolved in deionised water as 10 mM stock solutions and diluted in buffer before use. Fluo-4 AM ester (Invitrogen, UK) was dissolved in DMSO as a 1 mM stock solution, frozen immediately and stored at −20°C. On the day of use, it was diluted in buffer before use.
Results
A previous study reported that ATP and UTP both increased intracellular Ca 2+ in 1321N1-hP2Y 11 cells [10] , so initial experiments were carried out to confirm these data. Figure 1 shows that ATP (0.1-30 μM) evoked a rapid rise in intracellular Ca 2+ that was not maintained in the continued presence of ATP. The response amplitude was concentrationdependent, with an EC 50 =2.1 μM (95 % cl. 1.8--2.4 μM) (n=5). Surprisingly, in the same cells, even high concentrations of UTP (10 μM, n=6 and 100 μM, n=12) had no effect on intracellular Ca 2+ (Fig. 1) . To confirm that the UTP solution was active, we repeated these experiments in 1321N1-hP2Y 2 cells. Both nucleotides evoked rapid, transient rises in intracellular Ca 2+ in a concentration-dependent manner, with EC 50 values of 73 nM for UTP (95 % cl. 59-90 nM) and 176 nM for ATP (95 % cl. 156-199 nM) (n=4 each) (Fig. 2) . Indeed, UTP was slightly, but significantly more potent than ATP (P<0.01), but there was no difference in the maximum response. The lack of response to UTP in 1321N1-hP2Y 11 cells was not, therefore, due to a problem with the UTP solution.
These data show that we could not confirm the previous report [10] that UTP acts at the hP2Y 11 receptor to raise intracellular Ca
2+
. A possible explanation is that UTP did bind to the receptor, but for an unknown reason, did not activate it. To address this possibility, we determined if coadministration of UTP inhibited the response to ATP. Control responses were obtained to ATP (2 μM), a concentration close to its EC 50 . Superfusing 1321N1-hP2Y 11 cells with UTP (100 μM) for 10 min before reapplying ATP (2 μM) along with UTP (100 μM) had no significant effect on the response to ATP (Fig. 3a, b) .
Previous studies on hP2Y 11 receptors reported that ATP, but not UTP, induced accumulation of IPs [14, 15] , so we determined if UTP could inhibit this action of ATP. UTP (100 μM) alone did not alter basal level of IPs (not shown) nor was the rise in IPs elicited by ATP (3 μM) significantly affected by coadministration of UTP (100 μM) (Fig. 3c) . Thus two bioassays of receptor activity show that UTP is also not an antagonist at the human P2Y 11 receptor.
Discussion
Biased agonism, a process in which agonists bind the same receptor subtype, but activate different signalling pathways, is an important discovery that has implications for rational drug design, as it could lead to the development of new therapeutic agents that selectively stimulate beneficial functions of a GPCR. A previous study indicated that UTP is a biased agonist at human P2Y 11 receptors, inducing Ca 2+ mobilisation, so the aim of this study was characterise this action in detail. We were, however, unable to replicate UTP agonism. Nucleotides can also act as P2Y receptor antagonists [16] , but even high concentrations of UTP did not inhibit ATP in two bioassays of P2Y 11 receptor activity, Ca 2+ mobilisation and accumulation of IPs. Thus, we conclude that UTP is neither an agonist nor an antagonist at the human P2Y 11 receptor.
In this study, ATP evoked a rapid, concentration-dependent rise in intracellular Ca 2+ with an EC 50 of 2.1 μM, which is very close to the value of 2.7 μM seen in the earlier study that suggested biased agonism at the P2Y 11 receptor [10] . We reported previously an EC 50 of 8.1 μM for ATP-induced accumulation of IPs in the same cells [11] , which is similar to the value of 12.6 μM reported in the earlier study [10] for that response. Thus the potency of ATP seen in the two laboratories was essentially the same, suggesting similar levels of P2Y 11 receptor expression. This is not surprising, as the 1312N1-hP2Y 11 cell line used in both studies was generated by two of the present authors (CK, RAN) at the University of North Carolina. Despite this, we did not observe a rise in intracellular Ca 2+ when UTP was applied, even at 100 μM, a concentration that was almost maximally effective in the earlier study [10] . 1321 N1 cells are often used for expression of recombinant P2Y receptors because they not express any endogenous P2Y subtypes [6] , and the earlier study [10] confirmed the absence of mRNA for the UTPsensitive P2Y 2 and P2Y 4 receptors in the 1321N1-hP2Y 11 cells, eliminating those subtypes as the site of action of UTP. Thus it is unlikely that the inactivity of UTP in our study was due to differences in the expression of P2Y receptors.
Several other possible explanations for the difference in the responsiveness to UTP can be considered. Contamination by hydrolysis products of UTP is unlikely to be the cause of the discrepancy as the previous study monitored UTP purity by HPLC and eliminated its initial breakdown product, uridine 5′-diphosphate, using a creatine phosphokinase regenerating system. In contrast, the UTP solution used in the present study was ≥80 % pure, with ≤15 % UDP and ≤5 % UMP, so if hydrolysis products of UTP were to induce a Ca 2+ response, it would most likely have been seen in our study. Differences in the composition of the extracellular buffer are also unlikely to be an explanation, as in both studies, the 1321N1-hP2Y 11 cells were superfused with a Krebs-HEPES buffer containing 10 mM HEPES. Although White et al., [10] gave no further details of the buffer composition, any differences in the ions present would have to substantial in order to produce such a large difference in the responsiveness to UTP. Consequently, the most feasible explanation in our view is contamination of the UTP solution by a non-nucleotide agent acting at a receptor that is not a P2Y receptor.
In conclusion, we have demonstrated that ATP acts at the human P2Y 11 receptor to initiate a rise in cytoplasmic Ca 2+ , but this response is neither mimicked nor inhibited by high concentrations of UTP. Thus, contrary to a previous report, we have found no evidence that UTP is a biased agonist at the human P2Y 11 receptor.
